← All causality assessments
Expected pharmacological effect
Causality assessment · Expected pharmacological effect
Oxymorphone Hydrochloride and Dependence: is the FAERS signal real?
A written Bradford Hill assessment of one drug–event pair. The grade is a judgement about the signal, not a statement that this drug causes this event in any one person; FAERS counts are reports, not rates.
Oxymorphone Hydrochloride ↔ Dependence
n=4,904 co-reports · PRR 175.2 · ROR 302.9
Ruxolitinib is a JAK1/2 inhibitor for myelofibrosis. Co-reporting of myelofibrosis as a reaction is a coding artifact: patients on ruxolitinib for myelofibrosis have the indication recorded as the AE. 499 co-reports (PRR 15.6).
Coding artifact: myelofibrosis is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✗ No ClinicalTrials.gov results-posting trial in the top search hits for Oxymorphone captured dependence as a tracked adverse event in a usable structure. Myelofibrosis is the indication; trials do not track it as an AE.